Yahoo! Finance Search - Finance Home - Yahoo! - Help

Friday, March 31 2017 2:43am ET - U.S. Markets open in 6 hours and 47 minutes.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Friday, Mar 31, 2017
·Changing Demographics Offer Novartis a Strong Growth Opportunity
- 1 hour, 37 minutes ago
Thursday, Mar 30, 2017
·Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
PR Newswire - 1 hour, 51 minutes ago
·Why Have Novartis’s Valuation Multiples Fallen?
- Thu 3:13 pm ET
·Eczema Drug Dupixent Reports Positive Survey
at Investopedia - Thu 12:53 pm ET
·Reduced Co-pays May Boost Demand for Entresto
- Thu 10:36 am ET
·What Wall Street Analysts Estimate for GlaxoSmithKline
- Thu 10:36 am ET
·Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
- Thu 9:30 am ET
·Viagra May Be Soon Be Sold Without a Prescription in the UK
at Investopedia - Thu 9:16 am ET
·What Could Boost Medicare Demand for Novartis’s Entresto?
- Thu 9:06 am ET
·GlaxoSmithKline’s Consumer Healthcare Segment in 2016
- Thu 9:06 am ET
·Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
GlobeNewswire - Thu 8:01 am ET
·A Look Back at Eli Lilly’s 2016 Revenue Trends
- Thu 7:37 am ET
·Why Entresto Could Become Key Growth Driver for Novartis in 2017
- Thu 7:36 am ET
·Performance of GlaxoSmithKline’s Vaccines Business in 2016
- Thu 7:36 am ET
·U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information
PR Newswire - Thu 7:00 am ET
·Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Business Wire - Thu 6:59 am ET
·Novartis Makes Plans For Its Cancer-Killing T Cells
at Forbes.com - Wed 6:15 pm ET
·Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
at Investopedia - Wed 5:18 pm ET
Wednesday, Mar 29, 2017
·Eli Lilly’s Valuation Compared to Its Peers’
- Wed 4:50 pm ET
·Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed 4:07 pm ET
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?